These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Concomitant CIS on TURBT does not impact oncological outcomes in patients treated with neoadjuvant or induction chemotherapy followed by radical cystectomy. Vasdev N; Zargar H; Noël JP; Veeratterapillay R; Fairey AS; Mertens LS; Dinney CP; Mir MC; Krabbe LM; Cookson MS; Jacobsen NE; Gandhi NM; Griffin J; Montgomery JS; Yu EY; Xylinas E; Campain NJ; Kassouf W; Dall'Era MA; Seah JA; Ercole CE; Horenblas S; Sridhar SS; McGrath JS; Aning J; Shariat SF; Wright JL; Morgan TM; Bivalacqua TJ; North S; Barocas DA; Lotan Y; Grivas P; Stephenson AJ; Shah JB; van Rhijn BW; Daneshmand S; Spiess PE; Holzbeierlein JM; Thorpe A; Black PC World J Urol; 2019 Jan; 37(1):165-172. PubMed ID: 29882105 [TBL] [Abstract][Full Text] [Related]
6. Pathologic response in patients receiving neoadjuvant chemotherapy for muscle-invasive bladder cancer: Is therapeutic effect owing to chemotherapy or TURBT? Brant A; Kates M; Chappidi MR; Patel HD; Sopko NA; Netto GJ; Baras AS; Hahn NM; Pierorazio PM; Bivalacqua TJ Urol Oncol; 2017 Jan; 35(1):34.e17-34.e25. PubMed ID: 27639777 [TBL] [Abstract][Full Text] [Related]
7. The effect of concomitant carcinoma in situ on neoadjuvant chemotherapy for urothelial cell carcinoma of the bladder: inferior pathological outcomes but no effect on survival. Parker WP; Ho PL; Melquist JJ; Scott K; Holzbeierlein JM; Lopez-Corona E; Kamat AM; Lee EK J Urol; 2015 May; 193(5):1494-9. PubMed ID: 25451834 [TBL] [Abstract][Full Text] [Related]
8. Tumor downstaging as an intermediate endpoint to assess the activity of neoadjuvant systemic therapy in patients with muscle-invasive bladder cancer. Martini A; Jia R; Ferket BS; Waingankar N; Plimack ER; Crabb SJ; Harshman LC; Yu EY; Powles T; Rosenberg JE; Pal SK; Vaishampayan UN; Necchi A; Wiklund NP; Mehrazin R; Mazumdar M; Sfakianos JP; Galsky MD Cancer; 2019 Sep; 125(18):3155-3163. PubMed ID: 31150110 [TBL] [Abstract][Full Text] [Related]
9. Comparative Effectiveness of Neoadjuvant Pembrolizumab Versus Cisplatin-based Chemotherapy or Upfront Radical Cystectomy in Patients with Muscle-invasive Urothelial Bladder Cancer. Li R; Nocera L; Rose KM; Raggi D; Naidu S; Mercinelli C; Cigliola A; Tateo V; Patanè D; Grass GD; Gilbert SM; Sexton WJ; Bandini M; Moschini M; Briganti A; Montorsi F; Spiess PE; Necchi A Eur Urol Oncol; 2024 Jun; 7(3):614-624. PubMed ID: 38184473 [TBL] [Abstract][Full Text] [Related]
10. Survival and oncologic outcomes of complete transurethral resection of bladder tumor prior to neoadjuvant chemotherapy for muscle-invasive bladder cancer. Pak JS; Haas CR; Anderson CB; DeCastro GJ; Benson MC; McKiernan JM Urol Oncol; 2021 Nov; 39(11):787.e9-787.e15. PubMed ID: 33865688 [TBL] [Abstract][Full Text] [Related]
11. Expression of nucleoside transporters and deoxycytidine kinase proteins in muscle invasive urothelial carcinoma of the bladder: correlation with pathological response to neoadjuvant platinum/gemcitabine combination chemotherapy. North S; El-Gehani F; Santos C; Ghosh S; Lai R; Cass CE; Mackey JR J Urol; 2014 Jan; 191(1):35-9. PubMed ID: 23851183 [TBL] [Abstract][Full Text] [Related]
12. Long term oncologic outcome in patients with bladder cancer after radical cystectomy: Impact of carcinoma in situ in the era of neoadjuvant chemotherapy. Amini E; Ahmadi N; Clifford TG; Hugen CM; Bazargani ST; Cai J; Miranda G; Sherrod AE; Daneshmand S; Djaladat H Int Urol Nephrol; 2019 Mar; 51(3):435-441. PubMed ID: 30706249 [TBL] [Abstract][Full Text] [Related]
13. Clinical outcome and quality of life in octogenarian patients with muscle-invasive urothelial carcinoma of the bladder treated with radical cystectomy or transurethral resection of the bladder tumor: a retrospective analysis of 143 patients. Rehme C; Fritsch B; Thomas L; Istin S; Burchert C; Hummel B; Baleanu-Curaj B; Reis H; Szarvas T; Ruebben H; Hadaschik B; Niedworok C Int Urol Nephrol; 2022 Jan; 54(1):71-79. PubMed ID: 34817753 [TBL] [Abstract][Full Text] [Related]
14. Neoadjuvant dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin with pegfilgrastim support in muscle-invasive urothelial cancer: pathologic, radiologic, and biomarker correlates. Choueiri TK; Jacobus S; Bellmunt J; Qu A; Appleman LJ; Tretter C; Bubley GJ; Stack EC; Signoretti S; Walsh M; Steele G; Hirsch M; Sweeney CJ; Taplin ME; Kibel AS; Krajewski KM; Kantoff PW; Ross RW; Rosenberg JE J Clin Oncol; 2014 Jun; 32(18):1889-94. PubMed ID: 24821883 [TBL] [Abstract][Full Text] [Related]
15. Absence of Tumor on Repeat Transurethral Resection of Bladder Tumor Does Not Predict Final Pathologic T0 Stage in Bladder Cancer Treated with Radical Cystectomy. Kukreja JB; Porten S; Golla V; Ho PL; Noguera-Gonzalez G; Navai N; Kamat AM; Dinney CPN; Shah JB Eur Urol Focus; 2018 Sep; 4(5):720-724. PubMed ID: 28753837 [TBL] [Abstract][Full Text] [Related]
17. Squamous Differentiation Predicts Poor Response to Cisplatin-Based Chemotherapy and Unfavorable Prognosis in Urothelial Carcinoma of the Urinary Bladder. Minato A; Fujimoto N; Kubo T Clin Genitourin Cancer; 2017 Dec; 15(6):e1063-e1067. PubMed ID: 28803791 [TBL] [Abstract][Full Text] [Related]
18. Optimization of Patient Selection for Neoadjuvant Chemotherapy in Muscle-invasive Urothelial Carcinoma of the Bladder. Hensley PJ; Goodwin J; Davenport DL; Strup SE; James A Clin Genitourin Cancer; 2018 Aug; 16(4):e851-e858. PubMed ID: 29548614 [TBL] [Abstract][Full Text] [Related]
19. Phase II study of neoadjuvant chemotherapy with four cycles of dose-dense MVAC followed by radical cystectomy in Korean patients with muscle-invasive or locally advanced urothelial carcinoma of bladder. Park K; Lee HJ; Kim TU; Ryu H; Ki YK; Hong YJ; Nam JK Asia Pac J Clin Oncol; 2023 Dec; 19(6):739-746. PubMed ID: 37461246 [TBL] [Abstract][Full Text] [Related]
20. Adjuvant Chemotherapy vs Observation for Patients With Adverse Pathologic Features at Radical Cystectomy Previously Treated With Neoadjuvant Chemotherapy. Seisen T; Jamzadeh A; Leow JJ; Rouprêt M; Cole AP; Lipsitz SR; Kibel AS; Nguyen PL; Sun M; Menon M; Bellmunt J; Choueiri TK; Trinh QD JAMA Oncol; 2018 Feb; 4(2):225-229. PubMed ID: 28837718 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]